Approval · Notice of Compliance 23652 · 2020
TECENTRIQ: Notice of Compliance 23652
Issued May 20, 2020
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
Issued with conditions (NOC/c): the company must confirm the benefit in further studies.
- Notice number
- 23652
- Date
- May 20, 2020
- Company
- Hoffmann-La Roche LimitedMississauga, Ontario, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Amendment of commitment 2a of the Letter of Undertaking dated March 22, 2017 issued under NDS control #196843, Fulfilment of commitment 2b of the Letter of Undertaking dated March 22, 2017 issued under NDS control #196843
- With conditions
- Yes (NOC/c)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TECENTRIQ | Not yet assigned | — |
Medicinal ingredients
- ATEZOLIZUMAB 60 MG per ML
- ATEZOLIZUMAB 0